Cancer drug access in your area

ScotlandNorthern IrelandEnter alt textNorth EastYorkshire and HumbersideWest MidlandsEast MidlandsWalesLondonEast AngliaSouth WestSouth East

The BBC contacted all Primary Care Trusts in England, Local Health Boards in Wales, and the NHS in Scotland and Northern Ireland.

Focusing on five specific drugs not officially approved for use on the NHS, we asked how many applications they had received from patients in the last financial year - and how many had been granted.

The drugs in question were, Avastin, for colon and breast cancer, Erbitux, for colon and lung cancer, Nexavar, for renal and liver cancer, Sutent, for renal cancer, and Tarceva, for lung and pancreatic cancer.

Access to the drugs was tightest in London, and easiest in the North West of England.

However, there were wide variations, even between neighbouring authorities and in some areas no requests for the drugs had been made.

EAST ANGLIA - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.

Primary Care Trust Avastin (Becacizumab) colon and breast cancer Erbitux (Cetuximab) colon and lung cancer Tarceva (Erlotinib) lung and pancreas cancer Sutent (Sunitinib) renal cancer Nexavar (Sorafenib) renal and liver cancer Total - requests granted/total applications (%)
Cambridgeshire 0/0 0/0 2/6 5/6 1/2 8/14 (57.1%)
East and North Hertfordshire /West Hertfordshire 0/less than 5 0/greater than 10 less than 5/more than 5 less than 5/ more than 10 less than 5/more than 5 Will not give exact figures due to patient confidentiality
Great Yarmouth and Waveney 0/0 0/2 1/1 0/1 No data 1/4 (25%)
Mid Essex 1/1 0/1 0/2 4/4 0/0 5/8 (62.5%)
Norfolk 0/2 1/2 1/1 1/6 3/5 6/16 (37.5%)
North East Essex 0/0 0/0 1/2 0/0 3/3 4/5 (80%)
Peterborough 0/0 0/0 2/2 0/0 0/0 2/2 (100%)
South East Essex Had no applications for any of the drugs N/A
South West Essex No data N/A
Suffolk N/A 0/1 0/0 0/1 5/5 5/7 (71.4%)
West Essex PCT 3/3 1/1 2/3 1/1 1/1 8/9 (88.9%)

Return

EAST MIDLANDS - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
PCT Avastin (Becacizumab) for Colon and Breast Cancer Erbitux (Cetuximab) for Colon and lung Cancer Tarceva (Erlotinib) for Lung and Pancreas Cancer Sutent (Sunitinib) for Renal Cancer Nexavar(Sorafenib) for Renal and Liver Cancer Total - requests granted/total applications (%)
Bassetlaw 0/1 0/0 0/1 3/3 0/0 3/5 (60%)
Derby City 0/0 0/0 0/0 1/3 0/0 1/3 (33.3%)
Derbyshire County 1/1 0/0 0/1 1/4 0/0 2/6 (33.3%)
Leicester City/ Leicestershire 0/0 1/4 6/6 14/16 0/1 21/27 (77.8%)
Lincolnshire Teaching 0/1 1/2 2/2 1/2 0/6 4/13 (36.7%)
North Lincolnshire 1/1 0/0 0/0 1/4 n/a 2/8 (25%)
Northamptonshire Teaching 0/1 0/0 8/12 7/12 0/2 14/27 (51.8%)
Nottingham City 0/0 0/0 0/0 0/3 0/3 0/6 (0%)
Nottinghamshire County Teaching 1/3 1/1 1/1 3/ 6 0/0 6/11 (54.5%)
Tameside and Glossop 2/2 1/1 0/0 1/1 0/0 4/4 (100%)

Return

LONDON - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
PCT Avastin (Becacizumab) for Colon and Breast Cancer Erbitux (Cetuximab) for Colon and lung Cancer Tarceva (Erlotinib) for Lung and Pancreas Cancer Sutent (Sunitinib) for Renal Cancer Nexavar(Sorafenib) for Renal and Liver Cancer Total - requests granted/total applications (%)
Barking and Dagenham 1/1 1/2 1/1 0/0 0/0 3/4 (75%)
Barnet 0/4 0/1 1/2 0/7 0/2 1/16 (6.3%)
Bexley 1/2 1/2 0/2 0/5 0/1 2/12 (16.7%)
Brent Teaching 0/0 1(1)*/2 1/3 2/4 0/0 4/8 (50%)
Bromley 0/2 0/1 4/7 4/9 0/0 8/19 (42.1%)
Camden No data
City and Hackney Teaching 0/0 1/3 5/9 1/1 0/0 7/13 (53.8%)
Croydon 5 or less/5 or less 0/0 5 or less all refused 5 or less/5 or less 5 or less all refused N/A
Ealing 0/1 1 (for 3 months)/1 0/0 1/1 0/0 2/3 (66.7%)
Enfield 0 of 0 0 of 2 5 of 9 4 of 4 0 of 1 9/16 (56.2%)
Greenwich Teaching 2/2 0/1 2/3 1/2 0/2 5/10 (50%)
Hammersmith and Fulham No data
Haringey Teaching 0/0 0/0 1/4 3/3 0/0 4/7 (57%)
Harrow 0/0 0/0 1/1 1/2 0/0 2/3 (66.7%)
Havering 10/10 1/1 3/3 1/1 0/0 15/15 (100%)
Hillingdon 0/2 0/5 0/0 1/2 0/1 1/10 (10%)
Hounslow 0/1 0/2 0/0 0(1)*/4 0/1 0/7 (0%)
Islington 1(1)*/2 0/0 5(1)*/8 0/0 0/3 6/11 (54.5%)
Kensington and Chelsea 0/0 0/2 1/1 0/0 0/2 1/5 (20%)
Kingston 0/0 0/0 0/0 0/2 0/0 0/2 (0%)
Lambeth 0/0 0/0 5/6 5/6 0/3 10/15 (66.7%)
Lewisham 0/0 0/3 1/1 6/6 1/1 8/11 (72.7%)
Newham 0/0 0/0 2/3 0/0 0/0 2/3 (66.7%)
Richmond and Twickenham 0/1 0/1 0/0 0/1 (1)*/1 0/3 (0%)
Southwark 0 of 0 1 of 2 4 of 8 7 of 9 0 of 0 12/19 63.2%
Sutton and Merton 0/0 0/0 0/3 3/11 1/1 4/15 (%)
Tower Hamlets No data
Waltham Forest 1/1 0/0 2/2 0/0 1/1 4/4 (100%)
Wandsworth 0/0 0/0 0/1 0/1 0/0 0/2 (0%)
Westminster 0/0 0/2 1/4 1/3 0/0 2/9 (22.2%)

* application withdrawn

Return

NORTHERN IRELAND - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
Combined results on behalf of all four health and social services boards Avastin (Becacizumab) for Colon and Breast Cancer Erbitux (Cetuximab) for Colon and lung Cancer Tarceva (Erlotinib) for Lung and Pancreas Cancer Sutent (Sunitinib) for Renal Cancer Nexavar(Sorafenib) for Renal and Liver Cancer Total - requests granted/total applications (%)
Combined results are on behalf of all four health and social services boards 0/ less than 5 requests 0/ less than 5 requests Unknown /less than 5 16/16 0/0 N/A

Return

NORTH EAST - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
PCT Avastin (Becacizumab) for Colon and Breast Cancer Erbitux (Cetuximab) for Colon and lung Cancer Tarceva (Erlotinib) for Lung and Pancreas Cancer Sutent (Sunitinib) for Renal Cancer Nexavar(Sorafenib) for Renal and Liver Cancer Total - requests granted/total applications (%)
County Durham/ Darlington 0/0 1/1 1(2)*/4 0/1 0/1 2/7 (32.6%)
Gateshead/ South of Tyne and Wear/ Sunderland Information not held
Hartlepool/ Middlesbrough/ North Tees/ Redcar and Cleveland No applications Not routinely funded Routinely funded Routinely funded Not routinely funded N/A
Newcastle/ North Tyneside/ Northumberland 0/3 0/1 5/7 1/2 0/1 6/14 (42.9%)

* application withdrawn

Return

NORTH WEST - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
PCT Avastin (Becacizumab) for Colon and Breast Cancer Erbitux (Cetuximab) for Colon and lung Cancer Tarceva (Erlotinib) for Lung and Pancreas Cancer Sutent (Sunitinib) for Renal Cancer Nexavar(Sorafenib) for Renal and Liver Cancer Total - requests granted/total applications (%)
Ashton, Leigh and Wigan 0/0 0/0 0/0 0/0 0/0 N/A
Blackburn With Darwen 0/0 0/1 0/0 2(1)*/3 1/1 3/5 (60%)
Blackpool 0/0 0/0 0/0 1/1 0/1 1/2 (50%)
Bolton 0/0 0/0 0/0 4/4 0/0 4/4 (100%)
Bury 0/0 0/0 0/0 2/2 0/1 2/3 (66.7%)
Central & Eastern Cheshire 0/0 0/0 0/0 8/8 0/0 8/8 (100%)
Central Lancashire 0/0 0/0 1/1 4/5 1/2 6/8 (75%)
Cumbria Teaching 1/3 0/1 2/2 4/4 0/1 7/11 (63.6%)
East Lancashire Teaching 0/0 1/1 0/0 13/13 1/1 15/15 (100%)
Halton and St Helens No applications Automatically funded Automatically funded Automatically funded Automatically funded N/A
Heywood, Middleton and Rochdale 0/0 2/2 0/0 1/1 0/0 3/3 (100%)
Knowsley 0/0 0/0 0/0 1/1 0/0 1/1 (100%)
Liverpool Low requests 0/0 Low requests Low requests 0/0 N/A
Manchester 0/0 0/0 0/0 0/3 0/0 0/3 (0%)
North Lancashire Teaching No data
Oldham 0/0 0/1 0/0 3/3 0/0 3/4 (75%)
Salford 1/1 1/1 0/0 1/3 0/0 3/5 (60%)
Sefton 0/2 0/0 0/0 0/0 0/0 0/2 (0%)
Stockport 0/0 0/0 0/0 3/5 0/0 3/5 (60%)
Tameside and Glossop 2/2 1/1 0/0 1/1 0/0 4/4 (100%)
Trafford 7/7 3/3 0/0 3/4 0/0 13/14 (92.9%)
Warrington No data
Western Cheshire 0/0 0/0 0/0 0/0 0/0 N/A
Wirral 0/0 0/0 1/1 2/2 0/0 3/3 (100%)

* application withdrawn

Return

SCOTLAND - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
PCT Avastin (Becacizumab) for Colon and Breast Cancer Erbitux (Cetuximab) for Colon and lung Cancer Tarceva (Erlotinib) for Lung and Pancreas Cancer Sutent (Sunitinib) for Renal Cancer Nexavar(Sorafenib) for Renal and Liver Cancer Total - requests granted/total applications (%)
Ayrshire and Arran 0/0 0/0 N/A 0/0 0/1 0/1(0%)
Borders 0/0 0/0 0/0 0/0 0/0 0/0 (0%)
Dumfries and Galloway 0/0 0/0 0/0 0/2 0/0 0/2 (0%)
Fife 0/0 0/0 N/A 1/1 1/1 (100%)
Forth Valley 0/0 0/1 N/A 1/1 0/0 1/2 (50%)
Grampian 0/0 2/2 1/3 ( 2 under discussion) 0/0 3/5
Greater Glasgow and Clyde 0/0 0/2 0/0 0/7 0/9 (0%)
Highland 0/0 0/0 0/0 0/0 0/0 N/A
Lanarkshire 0/0 0/1 0/0 0/0 0/0 (0%)
Lothian 0/1 0/0 n/a 0/5 0/2 0/8 (0%)
Orkney
Shetland 0/0 0/0 0/0 0/0 0/0 N/A
Tayside 0/0 1/1 0/3 0/3 1/7 (14.3%)
Western Isles No data

Return

THE SOUTH EAST - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
Primary Care Trust Avastin (Becacizumab) colon and breast cancer Erbitux (Cetuximab) colon and lung cancer Tarceva (Erlotinib) lung and pancreas cancer Sutent (Sunitinib) renal cancer Nexavar (Sorafenib) renal and liver cancer Total - requests granted/total applications (%)
Bedfordshire 0/1 1/1 3(1)*/4 2(1)*/4 1(2)*/4 7/14 (50%)
Berkshire East 0/0 0/11 0/3 3/9 0/0 3/23 (13.0%)
Berkshire West 1/1 1/1 1/2 7/8 2/2 12/14 (85.7%)
Buckinghamshire 1/2 0/1 4/6 13/15 0/0 18/24 (75%)
East Sussex Downs and Weald / Hastings and Rother Do not provide Avastin Do not provide Erbitux Will provide if patient meets their criteria Will provide if patient meets their criteria Will provide if patient meets their criteria Will not state number of applications
Eastern and Coastal Kent 0/0 2/4 0/3 4/10 6/6 12/23 (52.2%)
Hampshire 0/3 1/2 2/8 0/7 0/2 3/22 (13.6%)
Isle Of Wight 1/2 0/3 0/0 0/2 0/0 1/7 (14.3%)
Luton 1/2 (1 awaiting decision) 1/1 0/0 1 awaiting decision 1 awaiting decision 2/5 (40%)
Medway 0/0 1/1 0/0 0/0 0/0 1/1 (100%)
Milton Keynes 0/0 0/0 1/3 1/1 0/0 2/4 (50%)
Oxfordshire 0/0 0/0 2/2 1/13 0/1 3/17 (17.6%)
Portsmouth City Teaching 0/0 0/0 0/0 1/1 0/1 1/2 (50%)
Southampton City 0/0 0/0 0/0 1/1 0/0 1/1 (100%)
Surrey 0/1 0/5 3/17 19/29 0/4 22/56 (39%)
Sutton and Merton 0/0 0/0 0/3 3/11 1/1 4/15 (26.7%)
West Kent 0/0 0/2 3/10 4/11 2/7 9/30 (30%)
West Sussex 0/4 0/0 0(1)*/5 11/11 0/3 11/23 (47.8%)

* application withdrawn

Return

THE SOUTH WEST - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
Primary Care Trust Avastin (Becacizumab) colon and breast cancer Erbitux (Cetuximab) colon and lung cancer Tarceva (Erlotinib) lung and pancreas cancer Sutent (Sunitinib) renal cancer Nexavar (Sorafenib) renal and liver cancer Total - requests granted/total applications (%)
Bath and North East Somerset 1/1 0/0 0/0 2/4 0/1 3/6 (50%)
Bournemouth and Poole Teaching PCT No information held
Bristol 0/0 0/0 Since Oct 2006, low number for Tarceva Since Oct 2006, 9 requests for Sutent and Sorafenib Since Oct 2006, 9 requests for Sutent and Sorafenib N/A
Cornwall and Isles Of Scilly PCT 1/1 1/2 5/6 6/6 0/1 13/16 (81.3%)
Devon PCT 0/3 1/4 18/19 12/15 0/2 31/43 (72.1%)
Dorset PCT 0/0 0/0 1/3 5/8 1/1 7/12 (58.3%)
Gloucestershire 0/3 0/0 1/3 2/4 0/0 3/10 (30%)
North Somerset 0/0 0/0 2/4 0/1 0/0 2/5 (40%)
Plymouth Teaching 0/0 0/0 2/3 0/1 4/4 6/8 (75%)
Somerset No data No data No data 8/10* No data N/A
South Gloucestershire 0/0 0/0 0/1 0/1 1/3 1/5 (20%)
Swindon 0/0 0/0 1/1 0/1 1/1 2/3 (66.6%)
Wiltshire 2/3 0/0 5/5 0/4 0/0 7/12 (58.3%)
* Funded 8/10 requests for Sutent, and less than 5/6 , in 2006-08. Did not provide data for each year. For the other drugs there may have been less than five applications made or funded

Return

WALES - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.
PCT Avastin (Becacizumab) for Colon and Breast Cancer Erbitux (Cetuximab) for Colon and lung Cancer Tarceva (Erlotinib) for Lung and Pancreas Cancer Sutent (Sunitinib) for Renal Cancer Nexavar(Sorafenib) for Renal and Liver Cancer Total - requests granted/total applications (%)
Anglesey 0/0 0/0 0/0 0/0 0/0 N/A
Blaenau Gwent 1/1 * * 0/0 0/0 1/1(100%)
Bridgend 0/0 0/0 4/4 1/1 0/0 5/5 (100%)
Caerphilly No data No data 0/less than 5 0/less than 5 0/0 N/A
Cardiff 0/2 0/0 0/1 2/4 0/0 2/7(28.5%)
Carmarthenshire No data
Ceredigion 0/0 1/2 0/0 0/3 0/0 1/5(20%)
Conwy 0/0 0/0 0/0 0/0 0/0 N/A
Denbighshire 0/0 0/0 0/0 less than5/ less than 5 0/0
Flintshire No data N/A
Gwynedd 0/less than 5 0/0 less than 5/less than 5 0/0 0/less than five N/A
Merthyr Tydfil 0/0 0/0 less than 5/ less than 5 0/0 0/0 N/A
Monmouthshire 0/0 0/0 1/1 0/0 0/0 1/1 (100%)
Neath Port Talbot No data
Newport 0/0 0/0 0/less than 5 0/0 less than 5/less than 5 N/A
Pembrokeshire 1/1 2/4 2/2 3/4 0/0 8/11(72.7%)
Powys No data Since 2006, 30% of all requests approved Since 2006, 30% of all requests approved No data Since 2006, 30% of all requests approved N/A
Rhondda Cynon Taff 0/0 Less than 5/ less than 5 Less than 5/less than 5 less than 5/less than 5 0/less than 5 N/A
Swansea 0/1 1/5 0/2 0/1 0/4 1/13(7.6%)
Torfaen No data No data No data All approved/less than 5 0/0 N/A
Vale of Glamorgan No data
Wrexham 0/0 0/0 Less than 5/less than 5 0/0 0/0 N/A

*For Erbitus and Tarceva allocation made available to support agreement in 16 LBH's in south east and mid and west Wales

Return

THE WEST MIDLANDS- NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.

Primary Care Trust Avastin (Becacizumab) colon and breast cancer Erbitux (Cetuximab) colon and lung cancer Tarceva (Erlotinib) lung and pancreas cancer Sutent (Sunitinib) renal cancer Nexavar (Sorafenib) renal and liver cancer Total - requests granted/total applications (%)
Birmingham East and North 0/2 1/2 0/6 5/6 0/2 6/18 (33.3%)
Coventry Teaching 0/0 0/0 0/0 0/1 0/1 0/2 (0%)
Dudley 0/4 1/3 1/4 1/4 0/0 3/15 (20%)
Heart Of Birmingham Teaching 1/2 0/0 0/0 3/6 0/0 4/8 (50%)
Herefordshire No information available
North Staffordshire 1/1 0/1 1/4 0/0 1/3 3/9 (33.3%)
Sandwell* 1/2 1/1 1/1 6/6 1/2 N/A
Shropshire County 0/0 4/5 pending/1 0/0 0/0 4/6 (66.7%)
South Birmingham 0/1 0/0 3/4 6/9 2/6 11/20 (55%)
South Staffordshire 0/2 1/4 2/5 3/4 0/5 6/20 (30%)
Stoke On Trent 1/2 0/0 0/1 0/0 0/0 1/3 (33.3%)
Telford and Wrekin 0/0 0/0 0/0 1/1 0/1 1/2 (50%)
Walsall Teaching 0/0 7/7 1/1 5/8 1/1 14/17 (82.4%)
Warwickshire 0/0 0/0 0/1 3/7 0/0 3/8 (37.5%)
Wolverhampton City Will not break figures down for fear of undermining patient confidentiality
Worcestershire 2/5 0/0 3/3 4/14 1/1 10/23 (43.5%)

*PCT will only provide combined figures for 2006-2008 for fear of undermining patient confidentiality

Return

YORKSHIRE AND HUMBERSIDE - NUMBER OF ACCEPTED REQUESTS FOR KEY CANCER DRUGS, 2007-2008
In the table below, first figure shows requests accepted, second figure shows number of requests. For example, (2/3) indicates two requests granted, out of three, for a particular drug.

PCT Avastin (Becacizumab) for Colon and Breast Cancer Erbitux (Cetuximab) for Colon and lung Cancer Tarceva (Erlotinib) for Lung and Pancreas Cancer Sutent (Sunitinib) for Renal Cancer Nexavar(Sorafenib) for Renal and Liver Cancer Total - requests granted/total applications (%)
Barnsley 0/0 0/2 0/0 4/4 0/0 4/6 (66.7%)
Bradford and Airedale Teaching No info given
Calderdale No breakdown given - have funded No breakdown given - have funded No breakdown given - have funded N/A
Doncaster 1/1 0/1 12/12 7/7 0/0 20/21 (90.7%)
East Riding Of Yorkshire 1/2 1/2 6/7 10/12 1/1 19/24 (79.2%)
Hull Teaching 0/2 0/0 3/3 4/4 0/1 7/10 (70%)
Kirklees 0/0 0/0 1/1 2/2 0/0 3/3 (100%)
Leeds 1/1 0/0 30/30 12/23 0/0 43/54 (79.6%)
North Yorkshire and York 0/1 1/2 0/6 1/10 0/1 2/20 (10%)
Rotherham 0/0 1/2 1/1 2/2 4/5 (80%)
Sheffield 0/0 1/5 1/3 11/13 0/0 13/21 (61.9%)
Wakefield District 0/0 0/0 3/3 1/1 0/0 4/4 (100%)

Return




FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

PRODUCTS & SERVICES

Americas Africa Europe Middle East South Asia Asia Pacific